Compare Stocks: APHB, EPRX, PROK, and ARVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APHB Ampliphi Biosciences	$3.74 +3.3%	$4.89	$0.15 ▼ $1.37	$125.17M	N/A	842,200 shs	100,793 shs
ARVN Arvinas	$7.59 -2.6%	$8.70	$6.97 ▼ $14.51	$489.71M	1.75	829,821 shs	713,344 shs
EPRX Eupraxia Pharmaceuticals	$8.01 -1.8%	$7.18	$5.25 ▼ $9.32	$520.80M	1.07	526,841 shs	1.31 million shs
PROK ProKidney	$1.60 -4.8%	$1.68	$1.30 ▼ $3.48	$483.72M	1.7	1.58 million shs	2.16 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APHB Ampliphi Biosciences	+3.31%	-10.53%	-31.38%	-49.46%	+21.82%
ARVN Arvinas	0.00%	-8.44%	-17.86%	-5.54%	-1.81%
EPRX Eupraxia Pharmaceuticals	0.00%	-6.64%	+8.83%	+21.57%	+43.29%
PROK ProKidney	0.00%	-16.23%	-12.09%	-12.57%	-41.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APHB Ampliphi Biosciences	$3.74 +3.3%	$4.89	$0.15 ▼ $1.37	$125.17M	N/A	842,200 shs	100,793 shs
ARVN Arvinas	$7.59 -2.6%	$8.70	$6.97 ▼ $14.51	$489.71M	1.75	829,821 shs	713,344 shs
EPRX Eupraxia Pharmaceuticals	$8.01 -1.8%	$7.18	$5.25 ▼ $9.32	$520.80M	1.07	526,841 shs	1.31 million shs
PROK ProKidney	$1.60 -4.8%	$1.68	$1.30 ▼ $3.48	$483.72M	1.7	1.58 million shs	2.16 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APHB Ampliphi Biosciences	+3.31%	-10.53%	-31.38%	-49.46%	+21.82%
ARVN Arvinas	0.00%	-8.44%	-17.86%	-5.54%	-1.81%
EPRX Eupraxia Pharmaceuticals	0.00%	-6.64%	+8.83%	+21.57%	+43.29%
PROK ProKidney	0.00%	-16.23%	-12.09%	-12.57%	-41.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APHB Ampliphi Biosciences	0.00	N/A	N/A	N/A
ARVN Arvinas	2.30	Hold	$14.55	91.64% Upside
EPRX Eupraxia Pharmaceuticals	2.90	Moderate Buy	$17.80	122.22% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	650.00% Upside

Current Analyst Ratings Breakdown

Latest APHB, EPRX, PROK, and ARVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	EPRX Eupraxia Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/24/2026	EPRX Eupraxia Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/10/2026	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $21.00
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00
8/5/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$15.00 ➝ $11.00
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	$316.70M	1.55	N/A	N/A	$6.76 per share	1.12
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
PROK ProKidney	$818K	591.34	N/A	N/A	($3.36) per share	-0.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	-$80.80M	$0.10	75.91	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)

Latest APHB, EPRX, PROK, and ARVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APHB Ampliphi Biosciences	N/A	N/A	N/A
ARVN Arvinas	N/A	7.91	7.91
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
PROK ProKidney	N/A	8.36	8.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APHB Ampliphi Biosciences	N/A
ARVN Arvinas	95.19%
EPRX Eupraxia Pharmaceuticals	N/A
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
APHB Ampliphi Biosciences	N/A
ARVN Arvinas	7.30%
EPRX Eupraxia Pharmaceuticals	N/A
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APHB Ampliphi Biosciences	30	33.47 million	N/A	Not Optionable
ARVN Arvinas	246	64.52 million	59.81 million	Optionable
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
PROK ProKidney	231	302.32 million	181.91 million	Optionable

APHB, EPRX, PROK, and ARVN Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell?

September 21, 2026 | marketbeat.com

ProKidney (PROK) Stock Forecast & Price Target

September 19, 2026 | investing.com

ProKidney (NASDAQ:PROK) Trading 6% Higher - Still a Buy?

September 16, 2026 | marketbeat.com

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

September 11, 2026 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy?

September 4, 2026 | marketbeat.com

ProKidney Corp. (PROK) Options Chain - Yahoo Finance

August 26, 2026 | finance.yahoo.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

August 14, 2026 | seekingalpha.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Gets a Buy from Guggenheim

August 12, 2026 | theglobeandmail.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2026 | zacks.com

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

August 10, 2026 | manilatimes.netM

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

June 17, 2026 | insidermonkey.com

ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout

June 2, 2026 | bizjournals.com

ProKidney Appoints Kenneth Locke as Chief Technical Officer

June 2, 2026 | globenewswire.com

ProKidney shareholders reaffirm board and auditor at 2026 meeting

May 29, 2026 | tipranks.com

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

May 15, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APHB, EPRX, PROK, and ARVN Company Descriptions

Ampliphi Biosciences NYSEAMERICAN:APHB

$3.74 +0.12 (+3.31%)

As of 09/25/2026

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Arvinas NASDAQ:ARVN

$7.59 -0.20 (-2.57%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.58 0.00 (-0.07%)

As of 09/25/2026 07:30 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.01 -0.15 (-1.84%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$8.01 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

ProKidney NASDAQ:PROK

$1.60 -0.08 (-4.76%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.64 +0.04 (+2.44%)

As of 09/25/2026 07:58 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APHB, EPRX, PROK, and ARVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APHB, EPRX, PROK, and ARVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APHB, EPRX, PROK, and ARVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APHB, EPRX, PROK, and ARVN Company Descriptions

Ampliphi Biosciences NYSEAMERICAN:APHB

Arvinas NASDAQ:ARVN

Eupraxia Pharmaceuticals NASDAQ:EPRX

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APHB, EPRX, PROK, and ARVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APHB, EPRX, PROK, and ARVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APHB, EPRX, PROK, and ARVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APHB, EPRX, PROK, and ARVN Company Descriptions

Ampliphi Biosciences NYSEAMERICAN:APHB

Arvinas NASDAQ:ARVN

Eupraxia Pharmaceuticals NASDAQ:EPRX

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools